Athira Pharma, Inc. (ATHA) NASDAQ
$0.54 (0.02) (-3.65%)
Market Cap: $20.81M
As of 09/06/24 04:00 PM EDT. Market closed.
Athira Pharma, Inc. (ATHA)
NASDAQ
$0.54
(0.02) (-3.65%)
Market Cap: $20.81M
As of 09/06/24 04:00 PM EDT. Market closed.
Add to Portfolio
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as ... read more
COMPANY PROFILE
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Mark J. Litton M.B.A., Ph.D.
Full Time Employees
65
CEO Compensation (Base)
$585,000
CEO Compensation (Total)
$2.26M
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Mark J. Litton M.B.A., Ph.D.
Full Time Employees
65
CEO Compensation (Base)
$585,000
CEO Compensation (Total)
$2.26M
URL
Address
18706 North Creek Parkway, WA, Bothell, 98011.
PRICE CHART FOR ATHIRA PHARMA, INC.
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$0.56
Previous Close
$0.56
Days Range
$0.52 - $0.58
52 week range
$0.52 - $4.30
Volume
1,939,564
Avg. Volume (30 days)
533,553
Market Cap
$20.81M
Dividend Yield
-
P/E
(0.18)
Shares Outstanding
38,439,400
Open
$0.56
Previous Close
$0.56
Days Range
$0.52 - $0.58
52 week range
$0.52 - $4.30
Volume
1,939,564
Avg. Volume (30 days)
533,553
Market Cap
$20.81M
Dividend Yield
-
P/E
(0.18)
Shares Outstanding
38,439,400
FINANCIAL STATEMENTS FOR ATHIRA PHARMA, INC.
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR ATHIRA PHARMA, INC.
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Gengos Andrew | CFO and Chief Business Officer | May 20, 2024 | Option Exercise | $1.34 | 10,000 | 13,400 | 93,804 | Sep 05, 2024, 07:51 PM |
| Gengos Andrew | CFO and Chief Business Officer | Sep 05, 2024 | Sale | $0.57 | 1,272 | 720 | 97,532 | Sep 05, 2024, 07:51 PM |
| Lenington Rachel | COO and CDO | Sep 05, 2024 | Sale | $0.57 | 2,525 | 1,429 | 20,870 | Sep 05, 2024, 07:50 PM |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | May 20, 2024 | Option Exercise | $1.34 | 4,953 | 6,637 | 85,209 | Sep 05, 2024, 07:49 PM |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Sep 05, 2024 | Sale | $0.57 | 2,525 | 1,429 | 92,684 | Sep 05, 2024, 07:49 PM |
| Worthington Mark | GENERAL COUNSEL | May 20, 2024 | Option Exercise | $1.34 | 10,000 | 13,400 | 44,452 | Sep 05, 2024, 07:48 PM |
| Worthington Mark | GENERAL COUNSEL | Sep 05, 2024 | Sale | $0.57 | 2,525 | 1,429 | 51,927 | Sep 05, 2024, 07:48 PM |
| Litton Mark James | President and CEO | Sep 05, 2024 | Sale | $0.57 | 5,032 | 2,848 | 159,365 | Sep 05, 2024, 07:47 PM |
| Romano Kelly A | Director | Jun 24, 2024 | Buy | $2.42 | 27,400 | 66,179 | 80,715 | Jun 25, 2024, 07:21 PM |
| Romano Kelly A | Director | Jun 21, 2024 | Buy | $2.26 | 15,000 | 33,872 | 53,315 | Jun 25, 2024, 07:21 PM |
| Lenington Rachel | COO AND CDO | Jan 05, 2024 | Sale | $2.91 | 2,412 | 7,019 | 13,395 | Feb 16, 2024, 04:40 PM |
| Litton Mark James | CEO | Jan 05, 2024 | Sale | $2.91 | 4,820 | 14,026 | 144,397 | Feb 16, 2024, 04:38 PM |
| Worthington Mark | GENERAL COUNSEL | May 18, 2023 | Option Exercise | $2.41 | 7,767 | 18,718 | 26,864 | Feb 16, 2024, 04:37 PM |
| Worthington Mark | GENERAL COUNSEL | Jan 05, 2024 | Sale | $2.91 | 2,412 | 7,019 | 34,452 | Feb 16, 2024, 04:37 PM |
| Gengos Andrew | CFO AND CHIEF BUSINESS OFFICER | Jan 05, 2024 | Sale | $2.91 | 1,208 | 3,515 | 83,804 | Feb 16, 2024, 04:34 PM |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | May 18, 2023 | Option Exercise | $2.41 | 809 | 1,950 | 69,271 | Feb 16, 2024, 04:32 PM |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Nov 20, 2023 | Option Exercise | $1.34 | 3,397 | 4,552 | 72,668 | Feb 16, 2024, 04:32 PM |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | Jan 05, 2024 | Sale | $2.91 | 2,412 | 7,019 | 80,256 | Feb 16, 2024, 04:32 PM |
| Gengos Andrew | See Below | Jan 05, 2023 | Sale | $2.91 | 1,208 | 3,515 | 83,804 | Jan 08, 2024, 04:42 PM |
| Litton Mark James | Chief Executive Officer | Jan 05, 2024 | Sale | $2.91 | 4,820 | 14,026 | 144,397 | Jan 08, 2024, 04:40 PM |
| Worthington Mark | General Counsel | May 18, 2023 | Option Exercise | $2.41 | 7,767 | 18,718 | 26,864 | Jan 08, 2024, 04:38 PM |
| Worthington Mark | General Counsel | Jan 05, 2024 | Sale | $2.91 | 2,412 | 7,019 | 34,452 | Jan 08, 2024, 04:38 PM |
| CHURCH KEVIN | Chief Scientific Officer | Nov 20, 2023 | Option Exercise | $1.34 | 3,397 | 4,552 | 72,668 | Jan 08, 2024, 04:36 PM |
| CHURCH KEVIN | Chief Scientific Officer | May 18, 2023 | Option Exercise | $2.41 | 809 | 1,950 | 69,271 | Jan 08, 2024, 04:36 PM |
| CHURCH KEVIN | Chief Scientific Officer | Jan 05, 2023 | Sale | $2.91 | 2,412 | 7,019 | 80,256 | Jan 08, 2024, 04:36 PM |
| Lenington Rachel | Chief Operating Officer | Jan 05, 2024 | Sale | $2.91 | 2,412 | 7,019 | 13,395 | Jan 08, 2024, 04:35 PM |
| PERCEPTIVE ADVISORS LLC | Director | Dec 29, 2023 | Buy | $2.38 | 163,954 | 390,211 | 5,402,964 | Dec 29, 2023, 05:24 PM |
| PERCEPTIVE ADVISORS LLC | Director | Dec 28, 2023 | Buy | $2.44 | 409,598 | 999,419 | 5,239,010 | Dec 29, 2023, 05:24 PM |
| PERCEPTIVE ADVISORS LLC | Director | Dec 27, 2023 | Buy | $2.28 | 32,134 | 73,266 | 4,829,412 | Dec 29, 2023, 05:24 PM |
| Gengos Andrew | See Below | Jun 07, 2023 | Buy | $3.43 | 15,000 | 51,445 | 80,012 | Jun 09, 2023, 05:06 PM |
| Gengos Andrew | See Below | Jun 05, 2023 | Buy | $3.00 | 45,000 | 135,150 | 65,012 | Jun 06, 2023, 07:36 PM |
| Gengos Andrew | See Below | Jun 02, 2023 | Buy | $2.82 | 20,012 | 56,422 | 20,012 | Jun 06, 2023, 07:36 PM |
| MOEBIUS HANS | Chief Medical Officer | May 18, 2023 | Option Exercise | $2.41 | 7,764 | 18,711 | 73,600 | Jun 06, 2023, 07:35 PM |
| MOEBIUS HANS | Chief Medical Officer | Jun 02, 2023 | Option Exercise | $1.35 | 7,882 | 10,641 | 81,482 | Jun 06, 2023, 07:35 PM |
| PICKERING GRANT | Director | Mar 29, 2023 | Buy | $2.33 | 10,000 | 23,300 | 10,783 | Mar 31, 2023, 04:36 PM |
| PICKERING GRANT | Director | Mar 30, 2023 | Buy | $2.47 | 15,000 | 37,050 | 25,783 | Mar 31, 2023, 04:36 PM |
| JOHNSON JAMES A | Director | Mar 29, 2023 | Buy | $2.40 | 5,000 | 12,000 | 5,000 | Mar 30, 2023, 06:59 PM |
| CHURCH KEVIN | Chief Scientific Officer | Mar 24, 2023 | Option Exercise | $1.35 | 6,410 | 8,654 | 68,462 | Mar 27, 2023, 04:57 PM |
| Litton Mark James | Chief Executive Officer | Nov 18, 2022 | Option Exercise | $2.74 | 662 | 1,814 | 129,217 | Jan 31, 2023, 07:33 PM |
| CHURCH KEVIN | Executive VP, Research | Nov 18, 2022 | Option Exercise | $2.74 | 657 | 1,800 | 62,052 | Jan 23, 2023, 05:26 PM |
| MILESON GLENNA | Chief Financial Officer | Nov 18, 2022 | Option Exercise | $2.74 | 763 | 2,091 | 109,930 | Dec 30, 2022, 04:58 PM |
| MILESON GLENNA | Chief Financial Officer | Dec 28, 2022 | Buy | $2.85 | 50,000 | 142,250 | 159,930 | Dec 30, 2022, 04:58 PM |
| Romano Kelly A | Director | Dec 02, 2022 | Buy | $3.29 | 30,000 | 98,700 | 38,315 | Dec 06, 2022, 08:31 PM |
| MOEBIUS HANS | Chief Medical Officer | Nov 15, 2022 | Buy | $3.29 | 5,000 | 16,442 | 65,836 | Nov 17, 2022, 07:10 PM |
| CHURCH KEVIN | Executive VP, Research | Oct 28, 2022 | Option Exercise | $1.35 | 3,700 | 4,995 | 61,395 | Oct 31, 2022, 08:17 PM |
| MOEBIUS HANS | Chief Medical Officer | Oct 13, 2022 | Option Exercise | $1.35 | 7,881 | 10,639 | 60,836 | Oct 17, 2022, 06:06 PM |
| PERCEPTIVE ADVISORS LLC | Director | Jun 30, 2022 | Buy | $2.99 | 1,101,362 | 3,293,072 | 4,797,278 | Jul 01, 2022, 02:24 PM |
| PERCEPTIVE ADVISORS LLC | Director | Jun 29, 2022 | Buy | $2.99 | 270,000 | 807,300 | 3,695,916 | Jul 01, 2022, 02:24 PM |
| MOEBIUS HANS | Chief Medical Officer | Jun 28, 2022 | Buy | $2.88 | 10,000 | 28,800 | 52,955 | Jun 30, 2022, 05:00 PM |
| Worthington Mark | General Counsel | May 18, 2022 | Option Exercise | $7.06 | 3,396 | 23,976 | 11,711 | Jun 24, 2022, 07:55 PM |
| Worthington Mark | General Counsel | Jun 23, 2022 | Sale | $2.69 | 2,614 | 7,032 | 19,097 | Jun 24, 2022, 07:55 PM |
| MOEBIUS HANS | Chief Medical Officer | May 18, 2022 | Option Exercise | $7.06 | 1,699 | 11,995 | 32,955 | Jun 24, 2022, 07:54 PM |
| MILESON GLENNA | Chief Financial Officer | May 18, 2022 | Option Exercise | $7.06 | 1,721 | 12,150 | 101,781 | Jun 24, 2022, 07:53 PM |
| MILESON GLENNA | Chief Financial Officer | Jun 23, 2022 | Sale | $2.69 | 2,614 | 7,032 | 109,167 | Jun 24, 2022, 07:53 PM |
| Litton Mark James | Chief Executive Officer | May 18, 2022 | Option Exercise | $7.06 | 757 | 5,344 | 116,515 | Jun 24, 2022, 07:51 PM |
| Litton Mark James | Chief Executive Officer | Jun 23, 2022 | Sale | $2.69 | 7,960 | 21,412 | 128,555 | Jun 24, 2022, 07:51 PM |
| Lenington Rachel | Chief Operating Officer | Jun 23, 2022 | Sale | $2.69 | 4,193 | 11,279 | 5,807 | Jun 24, 2022, 07:50 PM |
| CHURCH KEVIN | Executive VP, Research | Jun 23, 2022 | Sale | $2.69 | 2,614 | 7,032 | 57,695 | Jun 24, 2022, 07:25 PM |
| CHURCH KEVIN | Executive VP, Research | May 18, 2022 | Option Exercise | $7.06 | 243 | 1,716 | 47,809 | Jun 10, 2022, 05:53 PM |
| CHURCH KEVIN | Executive VP, Research | Jun 08, 2022 | Option Exercise | $1.35 | 2,500 | 3,375 | 50,309 | Jun 10, 2022, 05:53 PM |
| MILESON GLENNA | Chief Financial Officer | Apr 11, 2022 | Option Exercise | $10.64 | 3,000 | 31,920 | 100,060 | Apr 12, 2022, 07:36 PM |
| Romano Kelly A | Director | Mar 31, 2022 | Buy | $13.11 | 8,000 | 104,880 | 8,315 | Apr 01, 2022, 04:40 PM |
| CHURCH KEVIN | Executive VP, Research | Feb 18, 2022 | Option Exercise | $1.19 | 3,152 | 3,751 | 47,566 | Feb 18, 2022, 07:38 PM |
| Litton Mark James | Chief Executive Officer | Nov 18, 2021 | Option Exercise | $12.51 | 885 | 11,071 | 115,758 | Jan 31, 2022, 05:06 PM |
| MOEBIUS HANS | Chief Medical Officer | Nov 18, 2021 | Option Exercise | $12.51 | 829 | 10,371 | 31,256 | Jan 20, 2022, 05:25 PM |
| CHURCH KEVIN | Executive VP, Research | Nov 18, 2021 | Option Exercise | $12.51 | 96 | 1,201 | 44,414 | Jan 20, 2022, 05:24 PM |
| MILESON GLENNA | Chief Financial Officer | Nov 18, 2021 | Option Exercise | $12.51 | 931 | 11,647 | 90,755 | Jan 06, 2022, 05:08 PM |
| MILESON GLENNA | Chief Financial Officer | Jan 04, 2022 | Option Exercise | $1.35 | 6,305 | 8,512 | 97,060 | Jan 06, 2022, 05:08 PM |
| Litton Mark James | Chief Operating Officer | May 18, 2021 | Option Exercise | $14.45 | 867 | 12,528 | 64,433 | Aug 19, 2021, 05:05 PM |
| Litton Mark James | Chief Operating Officer | Aug 17, 2021 | Option Exercise | $1.35 | 50,440 | 68,094 | 114,873 | Aug 19, 2021, 05:05 PM |
| MOEBIUS HANS | Chief Medical Officer | May 18, 2021 | Option Exercise | $14.45 | 2,055 | 29,695 | 2,055 | Jul 21, 2021, 04:47 PM |
| MOEBIUS HANS | Chief Medical Officer | Jul 21, 2021 | Option Exercise | $1.35 | 28,372 | 38,302 | 30,427 | Jul 21, 2021, 04:47 PM |
| MILESON GLENNA | Chief Financial Officer | May 18, 2021 | Option Exercise | $14.45 | 1,554 | 22,455 | 83,519 | Jun 10, 2021, 06:48 PM |
| MILESON GLENNA | Chief Financial Officer | Jun 10, 2021 | Option Exercise | $1.35 | 6,305 | 8,512 | 89,824 | Jun 10, 2021, 06:48 PM |
| CHURCH KEVIN | Vice President of Discovery | May 18, 2021 | Option Exercise | $14.45 | 185 | 2,673 | 41,166 | Jun 10, 2021, 06:41 PM |
| CHURCH KEVIN | Vice President of Discovery | Jun 08, 2021 | Option Exercise | $1.04 | 3,152 | 3,278 | 44,318 | Jun 10, 2021, 06:41 PM |
| FLUKE JOHN M JR | Director | Feb 03, 2021 | Option Exercise | $1.21 | 29,003 | 35,119 | 143,884 | Feb 04, 2021, 08:18 PM |
| PERCEPTIVE ADVISORS LLC | Director | Jan 25, 2021 | Buy | $22.50 | 311,111 | 6,999,998 | 3,425,916 | Jan 27, 2021, 05:43 PM |
| PERCEPTIVE ADVISORS LLC | 10% Owner | Sep 22, 2020 | Buy | $17.00 | 1,058,824 | 18,000,008 | 3,114,805 | Sep 22, 2020, 07:11 PM |
| EDELMAN JOSEPH | Director | Sep 22, 2020 | Buy | $17.00 | 1,058,824 | 18,000,008 | 3,114,805 | Sep 22, 2020, 06:03 PM |
| RTW INVESTMENTS, LP | 10% Owner | Sep 18, 2020 | Buy | $17.00 | 750,000 | 12,750,000 | 2,668,913 | Sep 22, 2020, 05:03 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Gengos Andrew | CFO and Chief Business Officer | 05/20/2024 | 13,400 |
| Gengos Andrew | CFO and Chief Business Officer | 09/05/2024 | 720 |
| Lenington Rachel | COO and CDO | 09/05/2024 | 1,429 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | 05/20/2024 | 6,637 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | 09/05/2024 | 1,429 |
| Worthington Mark | GENERAL COUNSEL | 05/20/2024 | 13,400 |
| Worthington Mark | GENERAL COUNSEL | 09/05/2024 | 1,429 |
| Litton Mark James | President and CEO | 09/05/2024 | 2,848 |
| Romano Kelly A | Director | 06/24/2024 | 66,179 |
| Romano Kelly A | Director | 06/21/2024 | 33,872 |
| Lenington Rachel | COO AND CDO | 01/05/2024 | 7,019 |
| Litton Mark James | CEO | 01/05/2024 | 14,026 |
| Worthington Mark | GENERAL COUNSEL | 05/18/2023 | 18,718 |
| Worthington Mark | GENERAL COUNSEL | 01/05/2024 | 7,019 |
| Gengos Andrew | CFO AND CHIEF BUSINESS OFFICER | 01/05/2024 | 3,515 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | 05/18/2023 | 1,950 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | 11/20/2023 | 4,552 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER | 01/05/2024 | 7,019 |
| Gengos Andrew | See Below | 01/05/2023 | 3,515 |
| Litton Mark James | Chief Executive Officer | 01/05/2024 | 14,026 |
| Worthington Mark | General Counsel | 05/18/2023 | 18,718 |
| Worthington Mark | General Counsel | 01/05/2024 | 7,019 |
| CHURCH KEVIN | Chief Scientific Officer | 11/20/2023 | 4,552 |
| CHURCH KEVIN | Chief Scientific Officer | 05/18/2023 | 1,950 |
| CHURCH KEVIN | Chief Scientific Officer | 01/05/2023 | 7,019 |
| Lenington Rachel | Chief Operating Officer | 01/05/2024 | 7,019 |
| PERCEPTIVE ADVISORS LLC | Director | 12/29/2023 | 390,211 |
| PERCEPTIVE ADVISORS LLC | Director | 12/28/2023 | 999,419 |
| PERCEPTIVE ADVISORS LLC | Director | 12/27/2023 | 73,266 |
| Gengos Andrew | See Below | 06/07/2023 | 51,445 |
| Gengos Andrew | See Below | 06/05/2023 | 135,150 |
| Gengos Andrew | See Below | 06/02/2023 | 56,422 |
| MOEBIUS HANS | Chief Medical Officer | 05/18/2023 | 18,711 |
| MOEBIUS HANS | Chief Medical Officer | 06/02/2023 | 10,641 |
| PICKERING GRANT | Director | 03/29/2023 | 23,300 |
| PICKERING GRANT | Director | 03/30/2023 | 37,050 |
| JOHNSON JAMES A | Director | 03/29/2023 | 12,000 |
| CHURCH KEVIN | Chief Scientific Officer | 03/24/2023 | 8,654 |
| Litton Mark James | Chief Executive Officer | 11/18/2022 | 1,814 |
| CHURCH KEVIN | Executive VP, Research | 11/18/2022 | 1,800 |
| MILESON GLENNA | Chief Financial Officer | 11/18/2022 | 2,091 |
| MILESON GLENNA | Chief Financial Officer | 12/28/2022 | 142,250 |
| Romano Kelly A | Director | 12/02/2022 | 98,700 |
| MOEBIUS HANS | Chief Medical Officer | 11/15/2022 | 16,442 |
| CHURCH KEVIN | Executive VP, Research | 10/28/2022 | 4,995 |
| MOEBIUS HANS | Chief Medical Officer | 10/13/2022 | 10,639 |
| PERCEPTIVE ADVISORS LLC | Director | 06/30/2022 | 3,293,072 |
| PERCEPTIVE ADVISORS LLC | Director | 06/29/2022 | 807,300 |
| MOEBIUS HANS | Chief Medical Officer | 06/28/2022 | 28,800 |
| Worthington Mark | General Counsel | 05/18/2022 | 23,976 |
| Worthington Mark | General Counsel | 06/23/2022 | 7,032 |
| MOEBIUS HANS | Chief Medical Officer | 05/18/2022 | 11,995 |
| MILESON GLENNA | Chief Financial Officer | 05/18/2022 | 12,150 |
| MILESON GLENNA | Chief Financial Officer | 06/23/2022 | 7,032 |
| Litton Mark James | Chief Executive Officer | 05/18/2022 | 5,344 |
| Litton Mark James | Chief Executive Officer | 06/23/2022 | 21,412 |
| Lenington Rachel | Chief Operating Officer | 06/23/2022 | 11,279 |
| CHURCH KEVIN | Executive VP, Research | 06/23/2022 | 7,032 |
| CHURCH KEVIN | Executive VP, Research | 05/18/2022 | 1,716 |
| CHURCH KEVIN | Executive VP, Research | 06/08/2022 | 3,375 |
| MILESON GLENNA | Chief Financial Officer | 04/11/2022 | 31,920 |
| Romano Kelly A | Director | 03/31/2022 | 104,880 |
| CHURCH KEVIN | Executive VP, Research | 02/18/2022 | 3,751 |
| Litton Mark James | Chief Executive Officer | 11/18/2021 | 11,071 |
| MOEBIUS HANS | Chief Medical Officer | 11/18/2021 | 10,371 |
| CHURCH KEVIN | Executive VP, Research | 11/18/2021 | 1,201 |
| MILESON GLENNA | Chief Financial Officer | 11/18/2021 | 11,647 |
| MILESON GLENNA | Chief Financial Officer | 01/04/2022 | 8,512 |
| Litton Mark James | Chief Operating Officer | 05/18/2021 | 12,528 |
| Litton Mark James | Chief Operating Officer | 08/17/2021 | 68,094 |
| MOEBIUS HANS | Chief Medical Officer | 05/18/2021 | 29,695 |
| MOEBIUS HANS | Chief Medical Officer | 07/21/2021 | 38,302 |
| MILESON GLENNA | Chief Financial Officer | 05/18/2021 | 22,455 |
| MILESON GLENNA | Chief Financial Officer | 06/10/2021 | 8,512 |
| CHURCH KEVIN | Vice President of Discovery | 05/18/2021 | 2,673 |
| CHURCH KEVIN | Vice President of Discovery | 06/08/2021 | 3,278 |
| FLUKE JOHN M JR | Director | 02/03/2021 | 35,119 |
| PERCEPTIVE ADVISORS LLC | Director | 01/25/2021 | 6,999,998 |
| PERCEPTIVE ADVISORS LLC | 10% Owner | 09/22/2020 | 18,000,008 |
| EDELMAN JOSEPH | Director | 09/22/2020 | 18,000,008 |
| RTW INVESTMENTS, LP | 10% Owner | 09/18/2020 | 12,750,000 |
Load More Insider Transactions
FUNDS WITH A POSITION IN ATHIRA PHARMA, INC.
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 3,153,807 | 0.11% | No change | Other |
| BLACKROCK INC. | 676,244 | 0.00004% | 1.34% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 307,185 | 0.00007% | 2.31% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 271,488 | 0.00122% | 3.49% | Other |
| EASTERLY INVESTMENT PARTNERS LLC | 33,500 | 0.0078% | No change | Other |
CHANGE IN SHARES OUTSTANDING FOR ATHIRA PHARMA, INC.
STOCK BUYBACKS FOR ATHIRA PHARMA, INC.
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 06/30/2024
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
03/31/2024
0.15%
1Q
12/31/2023
0.73%
2Q
09/30/2023
0.85%
3Q
06/30/2023
1.00%
4Q
03/31/2023
1.20%
5Q
12/31/2022
1.40%
6Q
09/30/2022
1.49%
7Q
06/30/2022
1.89%
8Q
03/31/2022
2.09%
9Q
12/31/2021
2.71%
10Q
09/30/2021
2.86%
11Q
06/30/2021
3.13%
12Q
03/31/2021
7.28%
13Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR ATHIRA PHARMA, INC.
LOADING...